Figure 1.
Selection of study population. A total of 1045 patients with epithelial ovarian cancer were enrolled from January 2011 to December 2020. After exclusions, 631 patients comprised the final study population.
Figure 2.
Overall survival according to histological subtype in patients with epithelial ovarian cancer.
Table 1.
Patients baseline characteristics.
| Age Mean | 51 years (18–87) | |
|---|---|---|
| Stage | ||
| IA | 129 | 20.4% |
| IB | 26 | 4.1% |
| IC | 108 | 17.1% |
| IIA | 38 | 6.0% |
| IIB | 16 | 2.5% |
| IIC | 17 | 2.7% |
| IIIA | 60 | 9.5% |
| IIIB | 13 | 2.1% |
| IIIC | 146 | 23.1% |
| IV | 78 | 12.4% |
| Symptoms at diagnosis | ||
| Abdominal Pain | 534 (84.6%) | |
| PV Bleed | 259 (51.0% | |
| Bloating | 164 (26.0%) | |
| Incidental | 21 (3.3% | |
| Histological Cell Type | ||
| Serous (High grade) | 297 (46.8%) | |
| Serous (Low grade) | 19 (3.0%) | |
| Mucinous | 58 (9.2%) | |
| Clear Cell | 50 (7.9%) | |
| Endometrioid | 121 (19.2%) | |
| Cyst Adenocarcinoma | 50 (7.9%) | |
| Unclassified | 38 (6. %) | |
| CA-125 at Presentation | ||
| </= 100 | 331 (52.5) % | |
| > 100 | 291 (46.1%) | |
| N/A | 9 (1.4%) | |
| Initial Surgery | ||
| Optimal Surgery | 297 (47.1%) | |
| Suboptimal Surgery | 295 (46.6%) | |
| N/A | 40 (6.3%) | |
| Chemotherapy | ||
| Neoadjuvant Chemotherapy | 213 (33.75%) | |
| Adjuvant Chemotherapy | 263 (41.67%) | |
| N/A | 155 (24.56%) | |
| Maintenance Therapy | ||
| Bevacizumab | 68 (10.77%) | |
| Olaparib (PARPi) | 13 (2.06%) | |
| Recurrence or Death | ||
| Yes | 341 (54%) | |
| No | 283 (44.8%) | |
| Died du to other reason | 8 (1.3%) | |
| Type of recurrence | ||
| Platinum Sensitive | 255 (40.4%) | |
| Platinum resistant | 60 (9.7%) | |
| N/A | 315 (49.9% | |
| Current status | ||
| In remission | 197 (31.2%) | |
| Alive with disease progression | 83 (13.13%) | |
| Lost to follow up | 205 (32.4%) | |
| Dead | 147 (23.25%) | |
Figure 3.
Progression-free survival according to stage at presentation.
Table 2.
Multivariate analysis for progression free survival.
| Progression-free survival | B | SE | Wald | df | Sig. | Exp(B) | 95.0% CI for Exp(B) | |
|---|---|---|---|---|---|---|---|---|
| Lower | Upper | |||||||
| Age: > 50 vs. </= 50 years (referent) | −.262 | .141 | 3.461 | 1 | .063 | .769 | .583 | 1.014 |
| CA 125: > 100 vs. </=100 units/mL (referent) | .389 | .165 | 5.546 | 1 | .019 | 1.476 | 1.067 | 2.040 |
| Histology: serous high-grade ca vs. all other types (referent) | −.062 | .145 | .186 | 1 | .666 | .939 | .707 | 1.248 |
| Stage at presentation: III vs. II and I ((I was the referent) | 4.661 | 2 | .097 | |||||
| Stage at presentation: III vs. I | .012 | .235 | .002 | 1 | .960 | 1.012 | .638 | 1.603 |
| Stage at presentation: III vs. II | .356 | .187 | 3.625 | 1 | .057 | 1.428 | .990 | 2.061 |
| Surgery type: Suboptimal vs. optimal (referent) | −.003 | .158 | .000 | 1 | .983 | .997 | .731 | 1.359 |
| Relapse type: Platinum resistant vs. sensitive (referent) | .323 | .186 | 3.016 | 1 | .082 | 1.381 | .959 | 1.987 |
Table 3.
Multivariate analysis for overall survival.
| Overall survival | B | SE | Wald | df | Sig. | Exp(B) | 95.0% CI for Exp(B) | |
|---|---|---|---|---|---|---|---|---|
| Lower | Upper | |||||||
| Age: > 50 vs. </= 50 years (referent) | −.231 | .194 | 1.414 | 1 | .234 | .794 | .542 | 1.162 |
| CA 125: > 100 vs. >/= 100 units/mL (referent) | .092 | .225 | .167 | 1 | .683 | 1.096 | .706 | 1.703 |
| Histology: Serous high-grade ca vs. all other types (referent) | −.047 | .202 | .055 | 1 | .815 | .954 | .642 | 1.417 |
| Stage at presentation: IV, III, and II vs. I (I was the referent) | 5.698 | 3 | .127 | |||||
| Stage at presentation: II vs. I | .579 | .344 | 2.839 | 1 | .092 | 1.784 | .910 | 3.498 |
| Stage at presentation: III vs. I | .583 | .291 | 4.027 | 1 | .045 | 1.792 | 1.014 | 3.168 |
| Stage at presentation: IV vs. I | .808 | .359 | 5.064 | 1 | .024 | 2.244 | 1.110 | 4.536 |
| Type of surgery: suboptimal vs. optimal (referent) | .144 | .213 | .458 | 1 | .498 | 1.155 | .761 | 1.754 |
| Relapse: platinum resistant vs. sensitive (referent) | 1.062 | .548 | 3.758 | 1 | .053 | 2.891 | .988 | 8.455 |
| T_COV_ (relapse*time) | −.034 | .016 | 4.577 | 1 | .032 | .967 | .937 | .997 |
Figure 4.
Overall survival according to stage at presentation.
Figure 5.
Progression-free survival in patients undergoing suboptimal versus optimal primary debulking surgery.
Figure 6.
Overall survival in patients undergoing suboptimal versus optimal primary debulking surgery.